Acumen Extends Collaboration with Lonza to Add Product Manufacturing for Early Alzheimer’s

 

• Agreement builds upon a successful collaboration supporting the manufacture of sabirnetug (ACU193) drug substance (DS) for clinical studies in Alzheimer’s disease
• Extension to provide drug product (DP) manufacturing services for clinical and potential commercial supply from Lonza’s Visp, Switzerland site

https://www.globenewswire.com/news-release/2024/09/26/2953750/0/en/Acumen-Pharmaceuticals-Extends-Collaboration-with-Lonza-to-Add-Drug-Product-Manufacturing-of-Sabirnetug-for-Early-Alzheimer-s-Disease.html